Premium
Choice of first‐line therapy in metastatic melanoma
Author(s) -
Gibney Geoffrey T.,
Atkins Michael B.
Publication year - 2019
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.31774
Subject(s) - medicine , metastatic melanoma , melanoma , oncology , first line therapy , systemic therapy , first line , toxicity , targeted therapy , disease , second line , cancer , cancer research , breast cancer
Anti–PD‐1, alone or in combination with anti–CTLA‐4, and targeted BRAF therapies comprise the current first‐line systemic therapies for patients with metastatic melanoma. The decision on treatment choice is based on BRAF status, disease status, toxicity, efficacy profiles, comorbidities, and patient preferences.